1 in 8 Americans Now on GLP-1 Drugs: Why Microdosing Tirzepatide May Be the Smarter Path for Sustainable Fat Loss and Muscle Preservation

GLP-1 medications have exploded in popularity, with recent surveys showing that about 1 in 8 U.S. adults (roughly 12%) are currently taking a GLP-1 receptor agonist like semaglutide or tirzepatide for weight loss, diabetes, or related conditions. This marks a dramatic rise, as nearly 1 in 5 adults report having tried one at some point. While these drugs deliver impressive results, many users face challenges with muscle loss, gastrointestinal (GI) side effects, and sustainability at standard doses. At IncreaseMyT, we specialize in evidence-based protocols that optimize outcomes for men seeking better body composition, energy, and long-term health. We prefer tirzepatide for its dual GIP/GLP-1 action and focus on microdosing strategies paired with supportive compounds like Oxytocin to maximize fat loss while minimizing downsides.

The GLP-1 Boom: Why 1 in 8 People Are Turning to These Medications

KFF polling and other national surveys confirm that GLP-1 use has surged, driven by powerful effects on appetite, blood sugar, and weight. Higher usage appears among women aged 50-64, but interest spans broad demographics as obesity rates remain a challenge despite some population-level improvements. Standard dosing produces significant weight loss (often 15-20%+ body weight with tirzepatide), but rapid or aggressive deficits can lead to higher proportions of lean mass loss—up to 25-40% of total weight lost in some studies without supportive strategies. This is where microdosing enters as a strategic alternative for those prioritizing quality weight loss over speed.

Advantages of Microdosing Tirzepatide: Gentler, More Sustainable Results

Microdosing involves starting and maintaining lower-than-standard weekly doses of tirzepatide. Benefits include: Reduced GI side effects — Lower doses minimize nausea, vomiting, diarrhea, and constipation that often occur during titration or at higher maintenance levels. Many patients report better tolerability overall.

Steadier appetite regulation — Milder suppression allows sufficient calorie and protein intake to support training and recovery, rather than extreme restriction that can undermine metabolism.

Better muscle retention — Compared to dieting alone (which often triggers significant lean mass loss in a calorie deficit), microdosing tirzepatide—when combined with resistance training and adequate protein—helps shift the majority of weight loss toward fat mass. Studies and clinical observations show lean soft tissue preservation or even gains in some cases when lifestyle factors are optimized, unlike more aggressive approaches that can catabolize muscle.

Long-term adherence — Fewer side effects and a more gradual pace make it easier to stay consistent, supporting sustainable habits instead of yo-yo cycles.

For men optimizing testosterone and body composition, preserving muscle is critical for maintaining metabolic rate, strength, and hormone health.

Why IncreaseMyT Prefers Tirzepatide for Tolerability

Tirzepatide’s dual agonism (GLP-1 + GIP) often provides stronger appetite and metabolic effects than single GLP-1 agonists like semaglutide, while many patients experience a more favorable side-effect profile in real-world use—particularly when microdosed. We select pharmaceutical-grade tirzepatide sourced exclusively through licensed 503A compounding pharmacies under patient-specific prescriptions, ensuring USP-compliant sterile standards and physician oversight. This approach avoids unregulated “research” products and allows personalized dosing tailored to individual response, labs, and goals—key for men balancing weight loss with testosterone optimization.

Pairing Tirzepatide with Oxytocin: Double the Fat Loss, Fewer GI Issues

At IncreaseMyT, we enhance microdosing tirzepatide protocols by pairing it with Oxytocin. This strategic combination is designed to: Amplify fat loss — Potentially doubling the rate of targeted adipose reduction through complementary mechanisms.

Further reduce GI side effects — Helping patients tolerate therapy more comfortably, even at effective doses.

Support overall body recomposition — Preserving muscle while accelerating fat metabolism.

Combined with resistance training, high-protein nutrition, and hormone monitoring, this protocol helps men achieve leaner, more functional physiques without the pitfalls of standard high-dose GLP-1 use alone.

Safety, Considerations, and Clinical Take-Home Messages

• With 1 in 8 adults now on GLP-1s, microdosing tirzepatide offers a tolerable, muscle-friendly alternative to aggressive dieting or full-dose regimens.
• Advantages include better lean mass retention, reduced side effects, and improved long-term adherence when paired with proper training and nutrition.
• IncreaseMyT prioritizes tirzepatide for its dual action and pairs it with Oxytocin to enhance fat loss while mitigating GI discomfort.
• All protocols require medical supervision, lab monitoring, and licensed pharmacy sourcing—never unregulated products.
• Results vary based on starting point, adherence, and integration with testosterone optimization and lifestyle coaching.

Your Next Step at IncreaseMyT

At IncreaseMyT, we combine cutting-edge microdosing tirzepatide protocols with expert testosterone replacement therapy (TRT), peptides, and body-composition coaching. Our programs emphasize licensed 503A pharmacy sources, physician oversight, and personalized lab monitoring to deliver safe, effective results that preserve muscle, reduce fat, and restore vitality. Founder Todd and our clinical team focus on science-backed care for men who want sustainable fat loss, better energy, and peak performance—especially in the era of widespread GLP-1 use.

References & Sources:

1. KFF Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug (2025)
2. KFF Health Tracking Poll on GLP-1 Usage Trends
3. RAND Report: Nearly 12% of Americans Have Used GLP-1 Drugs for Weight Loss
4. Clinical observations and studies on lean mass preservation with GLP-1 therapies when combined with resistance training and adequate protein intake.
5. Real-world data on tirzepatide tolerability and dual GIP/GLP-1 agonism benefits, including microdosing approaches for improved sustainability.